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Unsafe injecting results in increased rates of hepatitis Cand HIV among populations of injecting drug users. Itis well established that it is unsafe to use needles or
syringes that have previously been used by another injecting
drug user.1 There is growing evidence that it is unsafe to share
a “cooker”, filter, or other injecting paraphernalia with
another injector.1 Most injecting drug users in Dublin
report sharing of syringes and injecting paraphelalia.2 In
Dublin, the prevalences of HIV and hepatitis C among inject-
ing drug users were found to be 1.2% and 61.8%
respectively.3 The incidence of hepatitis C among injecting
drug users has now been examined in North America,
Australia, and a number of European countries and has
ranged from 16 to 38 per 100 person years.1 4 5 We sought to
measure the incidence of hepatitis C and HIV among inject-
ing drug users in Dublin.
Table 1 Incidence of hepatitis C among injecting drug users in Dublin, by general and drug misuse characteristics
Number Seroconvertors
Person years at
risk (PYAR)
Incidence
(per 100 PYAR)
95% Confidence
intervals*
p
Value†
Total 100 67 101.6 66 51 to 84
Gender
Male 66 44 63.0 70 51 to 94
Female 34 23 38.6 60 38 to 89 0.54
Age ,(y)
Under 21 57 39 59.4 66 47 to 90
>21 43 28 42.3 66 44 to 96 0.98
Employment
Unemployed 88 63 89.5 70 54 to 90
Working (or at school) 12 4 12.2 33 9 to 84 0.13
Current sexual relationship
No partner/non-injecting partner 68 45 70.5 64 47 to 85
Partner injects 29 20 26.9 74 45 to 115 0.57
Unknown 3 2 4.2 48 5.8 to 172.0
Imprisoned before first test
No 55 35 65.1 54 37 to 75
Yes 36 25 26.9 93 60 to 137 0.03
Unknown 9 7 9.7 72 29 to 149
Time since onset of injecting (months)
1 to 12 67 47 63.6 74 54 to 98
13 or more 33 20 37.7 53 32 to 82 0.21
Principal drug injected
Heroin 72 45 75.8 59 43 to 79
Other or combination 28 22 25.9 85 53 to 129 0.17
Daily drug expenditure
Up to Ir£65 76 48 80.4 60 44 to 79
More than Ir£65 24 19 21.0 90 54 to 141 0.12
Route of opioid use‡ at first testing
Not all injected 18 7 27.1 26 10 to 56
All injected 67 50 53.6 93 69 to 123 0.006
Unknown 15 10 21.0 48 23 to 88
Benzodiazepine misuse§
No 50 33 55.3 60 41 to 84
Yes 45 29 40.3 72 48 to 103 0.46
Unknown 5 5 6.0 83 27 to 194
Imprisoned between tests
No 77 48 69.1 69 51 to 92
Yes 15 12 21.9 55 28 to 96 0.46
Unknown 8 7 10.7 65 26 to 135
Addiction treatment between tests
None or less than 3 months
treatment
67 42 56.2 75 54 to 101
More than 3 months 31 23 44.4 52 33 to 78 0.16
Unknown 2 2 1.1 182 22 to 657
*Confidence intervals for the incidence rate were calculated using the exact confidence limits for a Poisson count. †p Values were generated by
comparing incidence rates using the z test. ‡Benzodiazepines were the principal drug injected in three cases. §Benzodiazepine misuse was determined
on the basis of urine toxicology (Immunoassay EMIT test).
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PATIENTS, METHODS, AND RESULTS
Our methodology replicated that of van Beek.4 Since 1992, all
attenders at Trinity Court drug treatment centre with a history
of injecting were encouraged to consent to hepatitis C and HIV
testing during their addiction treatment. Data on the risk fac-
tors examined in this study were obtained via a semi-
structured interview conducted by a doctor, and included
information on demographic, treatment, forensic, and drug
misuse characteristics.
The initial screen for HIV antibodies involved two enzyme
linked immunosorbent assays (EIA). Positive tests were
confirmed with the western blot assay. Testing for hepatitis C
antibodies was performed with a second or third generation
EIA. The incidence of infections was measured using the per-
son years method.1 4 5 The date of the first negative test repre-
sented the starting point for all patients when calculating
their person years at risk. The end point was the date of the
last negative test for those who remained seronegative. The
estimated date of seroconversion was used as the end point for
those who seroconverted and this was calculated by finding
the midpoint between their negative and positive tests.
Three hundred and thirteen injecting drug users had a
negative hepatitis C test result when first tested between
November 1992 to September 1998. The incidence study
ended nine months later, and by this time 100 (31.9%) from
this group had undergone repeat testing during a subsequent
treatment episode. At the time of their initial negative test, the
median age of the cohort was 20.5 years and the median
period since commencement of injecting was just six months.
Eighteen patients were principally heroin smokers, but
reported injecting occasionally.
Regarding hepatitis C, 67 seroconverted during the study
period. The overall incidence of hepatitis C was 66/100 person
years (95% confidence intervals 51 to 84/100 person years). A
history of imprisonment was associated with significantly
increased hepatitis C incidence, while the group who usually
smoked heroin demonstrated reduced incidence (see table 1).
If the analysis is confined to the 74 patients who were retested
within 24 months, 45 (61%) seroconverted, yielding an
incidence of 100 infections/100 person years (95% confidence
intervals 73/100 to 134/100 person years).
During the study, 655 injecting drug users tested negative
for HIV and 164 (25.0%) underwent repeat testing. There were
two seroconversions. The incidence of HIV was 0.7/100 person
years (95% confidence intervals 0.1 to 2.5/100 person years ).
COMMENT
The detected hepatitis C incidence in Dublin is substantially
higher than the corresponding figures from studies of similar
design in similar settings elsewhere, and contrasts with a
comparatively low HIV incidence. However, these findings are
consistent with the prevalence rates of these infections in
Dublin.3 The cohort examined was young and comprised
mainly of recent onset injectors. Such characteristics are
among those most frequently associated with increased hepa-
titis C incidence.1 4 Programmes that aim to halt the spread of
hepatitis C will need to specifically target very recent onset
injecting drug users.
A minority of patients underwent repeat testing for either
HIV or hepatitis C. It is possible that those who did re-attend
for further assessment and addiction treatment were injecting
more frequently and more at risk. This could artificially inflate
the estimated incidences.
In common with van Beek’s study, we found that those who
had been imprisoned before their initial negative test demon-
strated higher hepatitis C incidence.4 The reason for this
association is unclear. As imprisonment predated entry into
the study, it cannot be causal. It has been suggested that those
who have been imprisoned may have a lifestyle that involves
increased risk taking behaviour in general, and this may
include increased unsafe injecting.4
Most heroin users smoke the drug before moving on to
injecting. Those who principally smoked heroin at the study
outset had a significantly lower hepatitis C incidence.
Strategies that might delay or reverse the progression form
heroin smoking to injecting should be developed and may
successfully reduce hepatitis C incidence.6
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